slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
225,241-225,270 of 319,975
03
The slide uses a hub-and-spoke diagram to connect the company brand to three core pillars: team, portfolio, and financials.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
04
SAB stands for Scientific Advisory Board.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
05
The slide uses a Gantt-style chart to represent clinical trial progress.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for therapeutic intervention.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
07
The slide uses a matrix structure to map clinical assets to specific indications and trial names.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
08
The diagram shows the MAPK pathway inhibition. The patient population data is presented as a simple table.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
09
The slide uses a KINOMEscan visualization to show selectivity.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
10
The chart is a classic waterfall plot used in oncology to show best response per patient/model.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
11
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
12
The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
18
The slide highlights US FDA Fast Track designation and superior PFS performance.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
19
The chart is a mirrored bar chart (diverging bar chart) showing AE frequency by grade.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
20
The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
21
The slide outlines two distinct clinical trial programs (SEACRAFT-1 and SEACRAFT-2) with specific stages, patient cohorts, and regulatory endpoints.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
22
The diagram shows the RAS/MAPK signaling pathway with ERAS-007 targeting ERK.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
23
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
24
The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
25
Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
26
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
27
Data cutoff 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
28
The diagram shows the RAS/MAPK/PI3K signaling pathway. ERAS-801 is shown as an EGFR inhibitor.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
30
The slide uses a biological diagram to illustrate EGFR mutations in GBM.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
32
The chart is a Kaplan-Meier survival plot comparing three treatment groups.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit